Effect of recombinant platelet-derived growth factor (Regranex) on wound closure in genetically diabetic mice.
Burns, especially those involving large surface areas, represent a complex wound healing problem. Platelet-derived growth factor (PDGF) is released by activated platelets to recruit inflammatory cells toward the wound bed. It has effects on promoting angiogenesis and granulation tissue formation. However, the effectiveness of topical PDGF on wound closure is variable, ranging from little improvement observed in pig models to dramatic improvement reported in a diabetic mouse model. Here, we sought to determine the effectiveness of commercially sold PDGF-BB (Regranex) on wound closure in genetically diabetic mice. C57BL/KsJ db+/db+ mice and its host strain bearing dorsal 1.5-cm wounds were divided into groups (n = 8 in each group) receiving topical application of either Regranex (10 microg/wound) or vehicle for 5 consecutive days after wounding. The rate of wound closure was analyzed using computerized planimetry. The amount of granulation tissue was determined histologically. Our data indicate that diabetic mice exhibit a significant delay in wound closure when compared with their host strain. Topical application of Regranex did not improve the time to wound closure but did significantly increase the amount of granulation tissue. Our current study using commercially available Regranex failed to reproduce the previously reported finding that PDGF improved wound closure in healing impaired genetically diabetic mice.
Department of Surgery and the Division of Plastic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
Rodney K
RK
Chan
Perry H
PH
Liu
Giorgio
G
Pietramaggiori
Shahrul I
SI
Ibrahim
Herbert B
HB
Hechtman
Dennis P
DP
Orgill
D000287:Administration, Topical; D043925:Angiogenesis Inducing Agents / Q000008:administration & dosage*; D000818:Animals; D000077214:Becaplermin; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000503:physiopathology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D010982:Platelet-Derived Growth Factor / Q000008:administration & dosage*; D020574:Proto-Oncogene Proteins c-sis; D013997:Time Factors; D014945:Wound Healing / Q000187:drug effects* / Q000502:physiology; D014949:Wounds, Nonpenetrating / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology*
D043925:Angiogenesis Inducing Agents; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D000077214:Becaplermin